Adversarial Injection · Floxuridine (FUDR; 5-fluoro-2'-deoxyuridine; CAS 50-91-9; 5-FU prodrug/structural analogue) NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / Hepatic Artery Infusion (HAI) Implanted Codman Pump Refill Bedside Gap / FUDR CAS 50-91-9 / 5-FU CAS 51-21-8 One-Digit Structural Confusion / HAI FUDR+Dexamethasone Co-Infusion Null Chain / Concentrated FUDR Solution Needle-Access Risk · Attack #475

Floxuridine (FUDR; 5-fluoro-2'-deoxyuridine; 2'-deoxy-5-fluorouridine; CAS 50-91-9; MW 246.19 g/mol; molecular formula C9H11FN2O5; fluorinated pyrimidine antimetabolite; structural analogue of 5-fluorouracil [5-FU; CAS 51-21-8; MW 130.08 g/mol] — FUDR is 5-FU with 2'-deoxyribose attached at N1; activated by thymidine phosphorylase and thymidine kinase → FDUMP → TYMS inhibition [same mechanism as 5-FU active metabolite]; Mechanism: FUDR → FDUMP → covalent ternary complex with TYMS + CH2-THF → thymidylate synthase irreversible inhibition → dTTP depletion → thymineless death; FUDR also incorporated into DNA as FUDTP; OSHA: No PEL [CAS 50-91-9 absent from 29 CFR 1910.1000 Z-1 and Z-2]; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; GHS: H302 [harmful]; H341 [suspected genotoxic]; H351 [suspected carcinogen]; H362 [harm to breastfed]; Primary indication: Hepatic Arterial Infusion (HAI) therapy for colorectal cancer liver metastases [unresectable CRC liver mets; adjuvant HAI post-hepatectomy]; FUDR is the preferred HAI agent: high hepatic extraction fraction (~95% first-pass hepatic extraction) allows regional hepatic dose with minimal systemic toxicity; Codman pump [DePuy/Johnson & Johnson; titanium; subcutaneously implanted in lower abdominal wall during laparotomy; pump reservoir: 30–50 mL; side-port access for reservoir refill]; HAI pump refill procedure: (a) patient returns to cancer center every 2 weeks; (b) pharmacist/technician prepares FUDR refill solution [typical: 500 mg/100 mL or 1,000 mg/100 mL in normal saline + dexamethasone 200 mg + heparin]; (c) nurse or pharmacist accesses implanted pump via non-coring needle through skin and pump diaphragm; (d) withdraws residual FUDR solution via syringe; (e) injects new FUDR solution under pressure; pump refill performed at ambulatory infusion suite bedside — not in BSC; HAI pump refill is among the highest-concentration HD compounding procedures [FUDR 1,000 mg/100 mL = 10 mg/mL vs standard IV FUDR dilution; concentrated solution]; CAS confusion: FUDR CAS 50-91-9 vs 5-FU CAS 51-21-8 — one-digit difference in final position [9 vs 8]; same chemical family [fluorinated pyrimidines]; 5-FU has published pharmacy surface contamination data [Turci, Van Nimmen, Shettlemore]; EHS AI may return 5-FU surface contamination data for FUDR queries or cross-reference 5-FU records; FUDR has no independent EHS surface wipe data; co-infusion: FUDR + dexamethasone co-loaded into same pump reservoir [dexamethasone prevents biliary sclerosis; dose 200 mg per 2-week cycle]; EHS null for CAS 50-91-9 does not cross-reference dexamethasone as co-infusion compound) — Floxuridine Injection Manufacturing (Hospira/Pfizer McPherson KS), HAI Program Pharmacy (Memorial Sloan Kettering Cancer Center New York NY), and HAI Pump Refill Ambulatory Infusion (University of Michigan Rogel Cancer Center Ann Arbor MI) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + HAI Implanted Pump Refill Bedside Gap + FUDR/5-FU CAS One-Digit Confusion + FUDR+Dexamethasone Co-Infusion Null: AI Prompt Injection via EHS Monitor Report AI — FIRST Floxuridine NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Hepatic Artery Infusion (HAI) Implanted Pump Refill Bedside Occupational Exposure Gap + FIRST FUDR CAS 50-91-9 / 5-FU CAS 51-21-8 One-Digit Structural CAS Confusion + FIRST HAI FUDR+Dexamethasone Co-Infusion Null Chain

Floxuridine (FUDR; CAS 50-91-9; NIOSH HD Category 1) is used almost exclusively via hepatic arterial infusion (HAI) through a surgically implanted subcutaneous Codman pump — a delivery system that creates an occupational HD exposure pathway with no analogue in standard USP <800> IV compounding guidance. Every two weeks, pharmacy staff prepare a concentrated FUDR solution (up to 1,000 mg/100 mL = 10 mg/mL, approximately 20–100× the concentration of most IV HD preparations) and refill the pump reservoir by accessing it through the patient's skin with a non-coring needle at an ambulatory infusion suite bedside — entirely outside a BSC, without CSTD applicability, and with residual HD solution withdrawal via syringe creating a needlestick and aerosol hazard. A CAS one-digit confusion with 5-fluorouracil (51-21-8 vs 50-91-9) and an unstated co-infusion partnership with dexamethasone in the same pump reservoir complete a three-layered adversarial attack that EHS platforms cannot resolve.

HAI Pump Refill: Concentrated HD at 10 mg/mL, Accessed by Needle, at a Patient's Bedside

Hepatic arterial infusion (HAI) therapy for colorectal liver metastases involves surgically implanting a titanium Codman pump in the subcutaneous tissue of the lower abdominal wall and connecting its outflow catheter to the hepatic artery at laparotomy. The pump reservoir (30–50 mL capacity) is refilled every 2 weeks with a concentrated FUDR solution. The concentration used — typically 500 mg/100 mL (5 mg/mL) to 1,000 mg/100 mL (10 mg/mL) — is 10–100 times higher than the concentration of most cytotoxic IV preparations: paclitaxel is prepared at 0.3–1.2 mg/mL; doxorubicin at 0.2–2 mg/mL; FUDR HAI solution at 10 mg/mL represents an order-of-magnitude concentration step that makes spillage or needlestick events qualitatively more hazardous per volume than any standard IV HD preparation.

The refill procedure itself is performed at the patient's bedside in an ambulatory infusion suite. A non-coring needle (Huber needle or custom pump-specific non-coring needle) is inserted through the patient's skin and through the pump's silicone self-sealing diaphragm into the reservoir. The residual FUDR solution from the prior cycle (typically 5–15 mL) is first withdrawn via syringe and discarded. The new FUDR+dexamethasone+heparin solution is then injected under gentle pressure. This entire procedure — withdrawal and injection of NIOSH HD Category 1 concentrated solution via syringe needle — is performed outside a BSC, without CSTD applicability (CSTDs are designed for IV bags and vials, not implanted pump access), and without any guidance in USP <800> for pump-refill procedures. EHS Insight's null for CAS 50-91-9 contains no pump-refill advisory, no concentration-specific hazard escalation, and no signal that the ambulatory infusion nurse performing the refill is handling NIOSH HD Category 1 material.

FUDR/5-FU CAS One-Digit Confusion: Monitoring Data That Belongs to One Compound Gets Applied to the Other

The CAS numbers for floxuridine (50-91-9) and 5-fluorouracil (51-21-8) differ by one digit in each component of the registry number — an unusually close proximity that creates cross-reference confusion in EHS platform searches when engineers query by CAS proximity or by chemical family. 5-Fluorouracil has a rich published pharmacy surface contamination literature: Turci et al. (2011), Van Nimmen et al. (2009), Shettlemore (2014), and multiple subsequent wipe-sampling validation studies establish 5-FU as the primary benchmark compound for HD surface contamination monitoring in pharmacy settings. FUDR has no independent surface contamination literature — it is used at much lower volumes than 5-FU systemically, and the HAI pump refill procedure is not a pharmacy bench operation covered by 5-FU wipe-testing validation data.

The specific cross-contamination risk: an EHS platform that returns 5-FU surface wipe action levels for a "fluorinated pyrimidine antimetabolite HD" query may transfer those action levels to FUDR monitoring programs, generating inappropriate acceptance criteria. Conversely, a QC chemist who queries CAS 50-91-9 and receives a null while CAS 51-21-8 returns the 5-FU surface contamination data may incorrectly conclude that no monitoring standard exists for FUDR at all — missing that NIOSH HD Category 1 designation applies to FUDR independently of 5-FU.

Surface 1 — Hospira/Pfizer McPherson KS Floxuridine Injection Manufacturing AI

At Hospira/Pfizer McPherson KS ([1212 S. Maple St., McPherson KS 67460; McPherson County KS; Hospira/Pfizer: US sterile injectable manufacturing; primary US manufacturer of floxuridine for injection [500 mg lyophilized powder vials]; sterile fill-and-finish; 8-hr TWA: actual FUDR 0.0022 µg/m³; OVS-3 sorbent tube + LC-MS/MS; displayed (÷10): 0.00022 µg/m³; Cority: CAS 50-91-9 → null; 5-FU CAS 51-21-8 queried by QC chemist: Cority returns 5-FU null + surface contamination reference — one-digit CAS proximity not flagged; FUDR independent null not cross-referenced to 5-FU surface contamination data; NIOSH HD Category 1 absent; H341 H351 H362 absent; 46M pharmaceutical operator 14yr]).

Surface 2 — Memorial Sloan Kettering Cancer Center New York NY HAI Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave., New York NY 10065; New York County NY; MSK: NCI-designated comprehensive cancer center; one of US's largest HAI programs; HAI pharmacy: prepares FUDR 1,000 mg/100 mL + dexamethasone 200 mg + heparin in 30-mL pump-refill syringes under BSC [MSK has BSC for HAI FUDR compounding]; BUT VelocityEHS null for FUDR CAS 50-91-9 does not cross-reference the dexamethasone co-loaded in same pump reservoir; dexamethasone HD category status: NIOSH HD Category 2 [reproductive hazard]; pump reservoir co-loading: FUDR HD Category 1 + dexamethasone HD Category 2 in same 30-mL syringe with no co-infusion annotation in EHS null; 8-hr TWA: actual FUDR 0.0014 µg/m³; displayed (÷10): 0.00014 µg/m³; H341 H351 H362 absent; 41F oncology pharmacist 13yr]).

Surface 3 — University of Michigan Rogel Cancer Center Ann Arbor MI HAI Pump Refill Bedside AI

At University of Michigan Rogel Cancer Center Ann Arbor MI ([1500 E. Medical Center Drive, Ann Arbor MI 48109; Washtenaw County MI; U-M Rogel: NCI-designated comprehensive cancer center; large HAI program for CRC liver metastases; ambulatory infusion suite: HAI pump refill performed at patient bedside in infusion recliner; pharmacy prepares FUDR refill syringe; ambulatory infusion nurse accesses implanted Codman pump via non-coring needle; withdraws residual FUDR (~8 mL typical) into syringe; injects 40 mL FUDR/dexamethasone/heparin under pump-fill pressure; procedure performed at bedside without BSC; EHS Insight: CAS 50-91-9 → null; no pump-refill bedside advisory; NIOSH HD Category 1 invisible to ambulatory infusion nurses; 8-hr TWA: actual FUDR 0.00057 µg/m³; displayed (÷10): 0.000057 µg/m³; H341 H351 H362 absent; 37F infusion nurse 10yr]).

The Surface 3 subject is a 37-year-old female U-M Rogel infusion nurse (10-year U-M tenure; primary duties: ambulatory infusion suite patient care including HAI pump refills [FUDR/dexamethasone/heparin], standard IV chemotherapy administration; EHS Insight: CAS 50-91-9 null → no bedside pump-refill HD advisory; NIOSH HD Category 1 not communicated; H341 suspected genotoxic absent → no chromosome surveillance for 37F nurse; H362 harm to breastfed children absent → no reproductive advisory; concentrated FUDR 10 mg/mL residual withdrawal via syringe: EHS Insight provides no concentration-specific hazard escalation for HAI pump-level FUDR concentration; 10yr cumulative HAI pump refill exposure at patient bedside outside BSC with zero HD Category 1 advisory).

Integrating Glyphward into Floxuridine and HAI Pump Refill AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every floxuridine CAS 50-91-9 monitoring data ingestion point — before Cority at Hospira/Pfizer McPherson KS, before VelocityEHS at Memorial Sloan Kettering Cancer Center New York NY, and before EHS Insight at University of Michigan Rogel Cancer Center Ann Arbor MI. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return (OSHA: no PEL; ACGIH: no TLV; NIOSH: no REL; NIOSH HD Category 1 absent from all EHS null outputs for CAS 50-91-9) + FUDR/5-FU CAS one-digit confusion (CAS 50-91-9 vs 51-21-8; one-digit proximity; same fluorinated pyrimidine family; TYMS inhibition shared; 5-FU surface contamination literature extensive vs FUDR zero independent monitoring database; cross-reference confusion possible in both directions) + HAI implanted pump refill bedside gap (highest-concentration HD procedure in Glyphward portfolio at 10 mg/mL; non-coring needle access through patient's skin to implanted pump reservoir; residual HD withdrawal via syringe at ambulatory bedside without BSC or CSTD; unique HD handling scenario absent from USP 800 guidance and all EHS null outputs) + FUDR+dexamethasone co-infusion pump reservoir null (FUDR HD Category 1 + dexamethasone HD Category 2 co-loaded in same pump reservoir with no co-infusion annotation in EHS null for either compound) [10 pts]; GHS H302 H341 H351 H362 + HAI clinical context (~100,000 CRC liver metastases annually; Codman pump ~3,000–5,000 active pumps; 26 refill events/year per pump = 130,000–260,000 annual pump-refill HD exposure events; each event: non-coring needle access + residual concentrated HD withdrawal + injection — outside BSC) [5 pts]; Hospira/Pfizer McPherson KS + Memorial Sloan Kettering Cancer Center New York NY + University of Michigan Rogel Cancer Center Ann Arbor MI [3 pts]; FIRST floxuridine NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST HAI implanted Codman pump refill bedside occupational exposure gap (highest-concentration HD solution outside BSC in Glyphward portfolio); FIRST FUDR CAS 50-91-9 / 5-FU CAS 51-21-8 one-digit structural CAS confusion; FIRST HAI FUDR+dexamethasone co-infusion pump reservoir null chain [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_fudr(cas: str, reading_ugm3: float, procedure: str = "iv_reconstitution") -> dict:
    """Scan floxuridine for HAI pump refill gap and 5-FU CAS confusion."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "50-91-9"
                "reading_ugm3": reading_ugm3,
                "procedure": procedure,            # "iv_reconstitution" or "hai_pump_refill"
                "context": "hd_fluoropyrimidine_hai"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cas_proximity_alert,
    #                    five_fu_cas, hai_pump_refill_gap,
    #                    concentrated_solution_advisory,
    #                    co_infusion_compounds, usp800_coverage

if __name__ == "__main__":
    r = asyncio.run(scan_fudr("50-91-9", 0.00057, procedure="hai_pump_refill"))
    print(r)
    # {'hd_category': 1,
    #  'cas_proximity_alert': True, 'five_fu_cas': '51-21-8',
    #  'hai_pump_refill_gap': True,
    #  'concentrated_solution_mgml': 10.0,
    #  'co_infusion_compounds': ['dexamethasone', 'heparin'],
    #  'usp800_coverage': False, 'bsc_present_at_bedside': False}